790 related articles for article (PubMed ID: 19723755)
1. Thyroid-associated ophthalmopathy after treatment for Graves' hyperthyroidism with antithyroid drugs or iodine-131.
Träisk F; Tallstedt L; Abraham-Nordling M; Andersson T; Berg G; Calissendorff J; Hallengren B; Hedner P; Lantz M; Nyström E; Ponjavic V; Taube A; Törring O; Wallin G; Asman P; Lundell G;
J Clin Endocrinol Metab; 2009 Oct; 94(10):3700-7. PubMed ID: 19723755
[TBL] [Abstract][Full Text] [Related]
2. Thyroid-associated ophthalmopathy; quality of life follow-up of patients randomized to treatment with antithyroid drugs or radioiodine.
Abraham-Nordling M; Wallin G; Träisk F; Berg G; Calissendorff J; Hallengren B; Hedner P; Lantz M; Nyström E; Asman P; Lundell G; Törring O;
Eur J Endocrinol; 2010 Oct; 163(4):651-7. PubMed ID: 20660002
[TBL] [Abstract][Full Text] [Related]
3. Radioiodine therapy versus antithyroid medications for Graves' disease.
Ma C; Xie J; Wang H; Li J; Chen S
Cochrane Database Syst Rev; 2016 Feb; 2(2):CD010094. PubMed ID: 26891370
[TBL] [Abstract][Full Text] [Related]
4. Changes in graves' ophthalmopathy after radioiodine and anti-thyroid drug treatment of Graves' disease from 2 prospective, randomized, open-label, blinded end point studies.
Chen DY; Schneider PF; Zhang XS; Luo XY; He ZM; Chen TH
Exp Clin Endocrinol Diabetes; 2014 Jan; 122(1):1-6. PubMed ID: 24203649
[TBL] [Abstract][Full Text] [Related]
5. Relation between therapy for hyperthyroidism and the course of Graves' ophthalmopathy.
Bartalena L; Marcocci C; Bogazzi F; Manetti L; Tanda ML; Dell'Unto E; Bruno-Bossio G; Nardi M; Bartolomei MP; Lepri A; Rossi G; Martino E; Pinchera A
N Engl J Med; 1998 Jan; 338(2):73-8. PubMed ID: 9420337
[TBL] [Abstract][Full Text] [Related]
6. Graves' hyperthyroidism: treatment with antithyroid drugs, surgery, or radioiodine--a prospective, randomized study. Thyroid Study Group.
Törring O; Tallstedt L; Wallin G; Lundell G; Ljunggren JG; Taube A; Sääf M; Hamberger B
J Clin Endocrinol Metab; 1996 Aug; 81(8):2986-93. PubMed ID: 8768863
[TBL] [Abstract][Full Text] [Related]
7. Risk factors for developing thyroid-associated ophthalmopathy among individuals with Graves disease.
Stein JD; Childers D; Gupta S; Talwar N; Nan B; Lee BJ; Smith TJ; Douglas R
JAMA Ophthalmol; 2015 Mar; 133(3):290-6. PubMed ID: 25502604
[TBL] [Abstract][Full Text] [Related]
8. Occurrence of ophthalmopathy after treatment for Graves' hyperthyroidism. The Thyroid Study Group.
Tallstedt L; Lundell G; Tørring O; Wallin G; Ljunggren JG; Blomgren H; Taube A
N Engl J Med; 1992 Jun; 326(26):1733-8. PubMed ID: 1489388
[TBL] [Abstract][Full Text] [Related]
9. The tale of radioiodine and Graves' orbitopathy.
Ponto KA; Zang S; Kahaly GJ
Thyroid; 2010 Jul; 20(7):785-93. PubMed ID: 20578895
[TBL] [Abstract][Full Text] [Related]
10. Treatment of Graves' hyperthyroidism--prognostic factors for outcome.
Alfadda A; Malabu UH; El-Desouki MI; Al-Rubeaan KA; Al-Ruhaily AD; Fouda MA; Al-Maatouq MA; Sulimani RA
Saudi Med J; 2007 Feb; 28(2):225-30. PubMed ID: 17268701
[TBL] [Abstract][Full Text] [Related]
11. [Comparison of the effectiveness of 131-I and antithyroid drugs in the treatment of Graves' disease in children].
Chen DY; Chen TH
Zhonghua Er Ke Za Zhi; 2005 Jul; 43(7):507-9. PubMed ID: 16083551
[TBL] [Abstract][Full Text] [Related]
12. Cloning and characterization of the novel thyroid and eye muscle shared protein G2s: autoantibodies against G2s are closely associated with ophthalmopathy in patients with Graves' hyperthyroidism.
Gunji K; De Bellis A; Li AW; Yamada M; Kubota S; Ackrell B; Wengrowicz S; Bellastella A; Bizzarro A; Sinisi A; Wall JR
J Clin Endocrinol Metab; 2000 Apr; 85(4):1641-7. PubMed ID: 10770210
[TBL] [Abstract][Full Text] [Related]
13. Cohort study on radioactive iodine-induced hypothyroidism: implications for Graves' ophthalmopathy and optimal timing for thyroid hormone assessment.
Stan MN; Durski JM; Brito JP; Bhagra S; Thapa P; Bahn RS
Thyroid; 2013 May; 23(5):620-5. PubMed ID: 23205939
[TBL] [Abstract][Full Text] [Related]
14. Graves' ophthalmopathy and 131I therapy.
Marcocci C; Bartalena L; Tanda ML; Manetti L; Dell'Unto E; Mazzi B; Rocchi R; Barbesino G; Pinchera A
Q J Nucl Med; 1999 Dec; 43(4):307-12. PubMed ID: 10731781
[TBL] [Abstract][Full Text] [Related]
15. Post-radioiodine De Novo Onset Graves' Ophthalmopathy: Case Reports and a Review of the Literature.
Batra R; Krishnasamy SK; Buch H; Sandramouli S
Semin Ophthalmol; 2015 May; 30(3):227-31. PubMed ID: 24409943
[TBL] [Abstract][Full Text] [Related]
16. Radioiodine therapy and Graves' disease - Myths and reality.
Plazinska MT; Sawicka-Gutaj N; Czarnywojtek A; Wolinski K; Kobylecka M; Karlińska M; Prasek K; Zgorzalewicz-Stachowiak M; Borowska M; Gut P; Ruchala M; Krolicki L
PLoS One; 2020; 15(1):e0226495. PubMed ID: 31929534
[TBL] [Abstract][Full Text] [Related]
17. Association between radioiodine therapy for Graves' hyperthyroidism and thyroid-associated ophthalmopathy.
El-Kaissi S; Bowden J; Henry MJ; Yeo M; Champion BL; Brotchie P; Nicholson GC; Wall JR
Int Ophthalmol; 2010 Aug; 30(4):397-405. PubMed ID: 20405165
[TBL] [Abstract][Full Text] [Related]
18. One-year follow-up of Graves' disease treatment by four different protocols of radioiodine administration.
Calegaro JU; De Freitas Gomes E; Bae SH; Ulyssea R; Casulari LA
Panminerva Med; 2000 Dec; 42(4):241-5. PubMed ID: 11294085
[TBL] [Abstract][Full Text] [Related]
19. Management of Graves' hyperthyroidism: present and future.
Bartalena L; Piantanida E; Gallo D; Ippolito S; Tanda ML
Expert Rev Endocrinol Metab; 2022 Mar; 17(2):153-166. PubMed ID: 35287535
[TBL] [Abstract][Full Text] [Related]
20. Hyperthyroidism. Current treatment guidelines.
Gittoes NJ; Franklyn JA
Drugs; 1998 Apr; 55(4):543-53. PubMed ID: 9561343
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]